Mirandahalle (Talk | contribs) |
Mirandahalle (Talk | contribs) |
||
Line 14: | Line 14: | ||
We submitted one part to the registry. However, we designed four total plasmids, three of which we were unable to prepare samples of by the submission deadline.</span></p> | We submitted one part to the registry. However, we designed four total plasmids, three of which we were unable to prepare samples of by the submission deadline.</span></p> | ||
<br> | <br> | ||
+ | <div class="content"> | ||
+ | <img src="https://static.igem.org/mediawiki/2016/5/59/T--UChicago--PlasmidMap.png"> | ||
+ | </div> | ||
+ | |||
<span class="ptitle"><a href="http://parts.igem.org/Part:BBa_K2176002">BBa_K2176002</a></span><br><br> | <span class="ptitle"><a href="http://parts.igem.org/Part:BBa_K2176002">BBa_K2176002</a></span><br><br> | ||
<p><span class="p"> | <p><span class="p"> |
Revision as of 20:53, 19 October 2016
We submitted one part to the registry. However, we designed four total plasmids, three of which we were unable to prepare samples of by the submission deadline.
This plasmid contains KaiC fused to a Gal4 activation domain, with a self-cleaving peptide linker, P2A, fusing it to KaiB. P2A cleaves itself during translation, causing the KaiC-Gal4AD and the KaiB to separate. We did this to allow us to control the exact ratio of KaiC, KaiB, and KaiA, and make sure it is constant and equal in every cell.